A Phase 3, Open-Label, Multi-center, Single Arm Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (MK-8415) Implant During Extended Use From 3 Years After Insertion in Females 35 Years of Age or Younger
Study About Extended Nexplanon Use in Females 18-35 Years Old
Sponsor: Merck Sharpe & Dohme Corp
Enrolling: Female Patients Only
Clinic Visits: 11
IRB Number: AAAT3564
U.S. Govt. ID: NCT04626596
Contact: Argelia Arias: 000-000-0000 / aa4153@cumc.columbia.edu
Additional Study Information: Nexplanon a contraceptive implant is currently approved for use up to 3 years. This study is looking to evaluate the contraceptive efficacy of Nexplanon during extended use for 2 more years (5 years total). You may be eligible if you are between the ages of 18-35 and are approaching 36 months from placement of your Nexplanon implant. Study participation would last 3 years and would require the completion of 11 study visits. Compensation for time and travel will be available upon completion of each study visit.
This study is closed
Investigator
Paula Castano, MD, MPH
Do You Qualify?
Are you currently using the Nexplanon implant as your current contraceptive method? Yes No
Would you be willing to use the Nexplanon as your only method of contraception during your participation in the study? Yes No
Are you planning to avoid pregnancy for the next 2 years? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Argelia Arias
aa4153@cumc.columbia.edu
000-000-0000
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE